Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer

Alberto Hernando-Calvo, Clinician scientist at Vall d’Hebron Barcelona Hospital, shared on X:

“Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in patients with proficient mismatch repair (pMMR) Colorectal Cancer (CRC) or pancreatic cancer at Princess Margaret Cancer Centre. Mentorship from Aaron Hansen and Lillian Siu and support from Pugh Lab, Benjamin Haibe-Kains labs, Ontario Institute for Cancer Research and others!”

A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

Authors: Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, Ben X. Wang, Jeffrey P. Bruce, Farnoosh Abbas-Aghababazadeh, Maria Vila-Casadesús, Enrique Sanz-Garcia, S.Y. Cindy Yang, Hal K. Berman, Ana Vivancos, Bernard Lam, Ilinca Lungu, Abdulazeez Salawu, Lee-Anne Stayner, Benjamin Haibe-Kains, Philippe L. Bedard, Lisa Avery, Albiruni R.A. Razak, Trevor J. Pugh, Anna Spreafico, Lillian L. Siu, Aaron R. Hansen.

Source: Alberto Hernando-Calvo/X